Format

Send to

Choose Destination
Neurol Clin. 2015 Nov;33(4):831-46. doi: 10.1016/j.ncl.2015.07.004.

Spinal Muscular Atrophy.

Author information

1
Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, USA; Department of Biological Chemistry and Pharmacology, The Ohio State University Wexner Medical Center, Columbus, OH 43210-1228, USA. Electronic address: stephen.kolb@osumc.edu.
2
Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.

Abstract

Spinal muscular atrophy is an autosomal-recessive disorder characterized by degeneration of motor neurons in the spinal cord and caused by mutations in the survival motor neuron 1 gene, SMN1. The severity of SMA is variable. The SMN2 gene produces a fraction of the SMN messenger RNA (mRNA) transcript produced by the SMN1 gene. There is an inverse correlation between SMN2 gene copy number and clinical severity. Clinical management focuses on multidisciplinary care. Preclinical models of SMA have led to an explosion of SMA clinical trials that hold great promise of effective therapy in the future.

KEYWORDS:

Motor neuron; SMN1; SMN2; Spinal muscular atrophy; Survival motor neuron gene

PMID:
26515624
PMCID:
PMC4628728
DOI:
10.1016/j.ncl.2015.07.004
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center